For the first quarter, total revenues increased 9% to $8.1 billion in comparison to the first quarter of 2024. Product sales grew 11%, primarily driven by 14% ...

An FDA-designated orphan drug that can target a key vulnerability in lung cancer shows promise in improving the efficacy of ...

Almost 50,000 lung cancer patients have not been seen on time over the last 10 years, with thousands currently waiting more ...

Dr. Bryant Lin explains how his stage IV lung cancer diagnosis didn’t defeat him but instead inspired a revolutionary class.

Relapsed/refractory (R/R) mature T and natural killer (NK)-cell lymphomas (TNKL) are aggressive blood cancers often resistant to frontline therapies. A team of Mass General Brigham researchers found ...

Study data reveal how a specific sequence of cancer therapies can improve outcomes for patients with hard-to-treat lymphomas.

The study results "signal unmet needs and potentially undertreated pain in patients with cancer,” researchers wrote.

Ladies and gentlemen, thank you for standing by, and welcome to Pulmonx first quarter 2025 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded ...